Omnicell (OMCL)
(Delayed Data from NSDQ)
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.48 USD
-0.78 (-1.72%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $44.31 -0.17 (-0.38%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NXGN vs. OMCL: Which Stock Is the Better Value Option?
LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop
by Zacks Equity Research
LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.
Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.
Omnicell (OMCL) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 23.88% and 2.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Q2 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in second-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Align Technology (ALGN) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Align Technology's (ALGN) segments report solid Q1 sales across geographies despite the pandemic-led business challenges.
Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.
Illumina (ILMN) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits an impressive performance by its Instruments segment in the first quarter of 2021 despite pandemic-led business disruptions.
Stryker (SYK) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.
Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates
by Zacks Equity Research
Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
Omnicell (OMCL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.
Here's Why You Should Hold on to Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its progress with its three-legged strategic, which is driving growth and an impressive 2025 roadmap.
Omnicell's (OMCL) Automated Dispensing Service Adopted by Aultman
by Zacks Equity Research
Omnicell's (OMCL) Autonomous Pharmacy vision receives another boost with the latest service adoption by Aultman.
Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays
by Zacks Equity Research
Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.
Omnicell (OMCL) Moves 4.9% Higher: Will This Strength Last?
by Zacks Equity Research
Omnicell (OMCL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Omnicell (OMCL) Up 0.8% Since Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Grows on New Services Amid Pandemic Woes
by Zacks Equity Research
Omnicell (OMCL) is progressing in autonomous pharmacy space by expanding portfolio and investing in the digital cloud-based platform.
Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments
by Zacks Equity Research
Thermo Fisher (TMO) records $3.2 billion of COVID-19 response revenues and accelerated growth in base business in Q4.
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in first-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Information industry. OMCL, NXGN and NH are well positioned to gain.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.